A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

NCT ID: NCT04547907

Last Updated: 2024-09-20

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 688 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-18
• Study Completion Date: 2024-12-31

Brief Summary

The aim of this study is to evaluates the efficacy of weekly nab-paclitaxel monotherapy compared to the standard regimen of docetaxel plus carboplatin, both supplemented with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.

Detailed Description

In order to compare the effects of nab-PHP and TCbHP chemotherapy regimens in the neoadjuvant treatment of HER2-positive breast cancer, this study randomly divided patients who met the inclusion criteria into 2 groups through a randomized control regimen： the neoadjuvant chemotherapy with 6*nab-PHP regimen group (experimental group): nab-paclitaxel 125mg/m2 on days 1, 8, and 15 every 21 days as one cycle; 6*TCbHP regimen (control group): docetaxel 75 mg/m2 + carboplatin (AUC=6) on day 1. Both groups will receive trastuzumab (loading dose 8 mg/kg followed by a maintenance dose of 6 mg/kg) on day 1 and pertuzumab (loading dose 840 mg followed by a maintenance dose of 420 mg) on day 1, every 21 days as one cycle.

Surgery will be performed after completion of neoadjuvant chemotherapy, with intraoperative excision of specimens (breast + axilla) for pathological evaluation.

Comparative analysis of pCR, EFS, iDFS and safety outcomes between the two groups will be conducted using appropriate statistical methods.

Safety evaluation will include the incidence of adverse events, incidence of serious adverse events, dose adjustment rate, and discontinuation rate.

Conditions

Breast Cancer,HER2-positive

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

nab-PHP

Nab-paclitaxel + trastuzumab+ patuzumab

Group Type: EXPERIMENTAL

Nab-paclitaxel+ trastuzumab+ patuzumab

Intervention Type: DRUG

Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

TCbHP

Docetaxel + carboplatin + trastuzumab + patuzumab

Group Type: ACTIVE_COMPARATOR

Docetaxel+ carboplatin+ trastuzumab + patuzumab

Intervention Type: DRUG

Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

Interventions

Nab-paclitaxel+ trastuzumab+ patuzumab

Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

Intervention Type: DRUG

Docetaxel+ carboplatin+ trastuzumab + patuzumab

Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

Intervention Type: DRUG

Other Intervention Names

nab-PHP regimen group; TCbHP regimen group

Eligibility Criteria

Inclusion Criteria

1. Age: 18-70 years;

2. Clinical T2-T4d, or T1c with axillary lymph node positivity;

3. Histopathologically confirmed HER2-positive invasive breast cancer; Note: HER2 positivity was determined by immunohistochemical (IHC) staining of 3+ or, if IHC 2+, by HER2 gene amplification as demonstrated by fluorescence in situ hybridization (FISH) assay；

4. Have clinically measurable lesions: Measurable lesions shown on ultrasound, mammography, or MR (optional) within 1 month before randomization;

5. No chemotherapy contraindications detected by organ and bone marrow function tests within 1 month before chemotherapy:

1. Neutrophil count absolute value ≧2.0×109/L;

2. Hemoglobin ≧ 100g/L;

3. Platelet count ≧100×109/L;

4. Total bilirubin <1.5 ULN (upper limit of normal);

5. Creatinine < 1.5×ULN

6. AST/ALT < 1.5×ULN;

6. Cardiac ultrasound: Left ventricular ejection fraction (LVEF ≥ 55%);

7. Reproductive age women, negative serum pregnancy test within 14 days before randomization;

8. ECOG score 0 or 1;

9. Signature of informed consent.

Exclusion Criteria

1. Stage IV (metastatic) breast cancer;

2. Bilateral breast cancer;

3. Patients who have received chemotherapy, endocrine therapy, targeted therapy, or radiotherapy for this disease;

4. Patients with a second primary malignancy, except for adequately treated skin cancer;

5. Major non-breast cancer-related surgical procedures within the past 4 weeks before enrollment, or patients have not fully recovered from such surgical procedures;

6. Severe heart disease or conditions that do not allow participation in the study, including but not limited to the following:

1. History of heart failure or systolic dysfunction (LVEF < 50%);

2. High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate > 100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-grade atrioventricular conduction blocks (i.e., Mobitz II second-degree atrioventricular block or third-degree atrioventricular block);

3. Angina pectoris requiring anti-anginal drug therapy;

4. Clinically significant valvular heart disease;

5. ECG showing a transmural myocardial infarction;

6. Uncontrolled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg);

7. Due to severe and uncontrolled other medical conditions, the investigator considers chemotherapy to be contraindicated;

8. Known history of allergy to any component of the study drugs; patients with a history of immune deficiency diseases, including HIV positivity, or patients with other acquired or congenital immune deficiency diseases, or a history of organ transplantation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Henan Cancer Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Zhenzhen Liu

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Zhenzhen Liu

Role: PRINCIPAL_INVESTIGATOR

Study Principal Investigator Henan Cancer Hospital

Locations

Henan cancer hospital

Zhengzhou, Henan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Zhenzhen Liu

Role: CONTACT

liuzhenzhen73@163.com

13603862755

Jiujun Zhu

Role: CONTACT

bigapple0601@126.com

13676962766

Facility Contacts

Zhenzhen Liu

Role: primary

liuzhenzhen73@126.com

17729798130

References

Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2025 Jan;26(1):27-36. doi: 10.1016/S1470-2045(24)00581-3. Epub 2024 Nov 26.

Reference Type: DERIVED

PMID: 39612919 (View on PubMed)

Other Identifiers

HELEN-006

Identifier Type: -

Identifier Source: org_study_id